

Contents lists available at ScienceDirect

Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtph



Commentary

Revision of the opinion on hydrolysed wheat proteins — Sensitisation only



Scientific Committee SCCS $^{\rm a,\,*}$, Pieter-Jan Coenraads $^{\rm b,\,1}$

- ^a European Commission, Directorate General for Health and Food Safety, 11, rue E. Ruppert, L-2920 Luxembourg, Luxembourg
- ^b University Medical Center Groningen, Groningen, The Netherlands

ARTICLE INFO

Article history:
Received 12 June 2015
Received in revised form
3 August 2015
Accepted 3 August 2015
Available online 14 August 2015

Keywords: SCCS Scientific opinion Cosmetic ingredients Hydrolysed wheat proteins Regulation 1223/2009 CAS 94350-06-8 222400-28-4 70084-87-6 100209-50-5 EC 305-225-0

1. Conclusion of the opinion

The SCCS is of the opinion that, in view of the numbers of reported cases of immediate-type contact urticarial and systemic allergic reactions, the overall risk of sensitization to Hydrolysed Wheat Proteins (HWP) appears to be low, with the exception of an 'epidemic' in Japan associated with one particular HWP product used in some brands of soap. Scientific concerns with regard to the use of HWP in cosmetic products include that (i) there is evidence that sensitisation to HWP is via exposure to cosmetics, not via food

and (ii) there are indications that the risk of sensitisation is higher when HWP's of higher molecular weight are used on the skin, in particular as an ingredient of products that have strong surfactant properties such as soaps and liquid soaps. The SCCS considers the use of hydrolysed wheat proteins safe for consumers in cosmetic products, provided that the maximum molecular weight average of the peptides in hydrolysates is 3.5 kDa.

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on the safety of hydrolysed wheat proteins in cosmetic products, submission I, 18 June 2014, SCCS/1534/14, revision of 22 October 2014.

SCCS members: U. Bernauer, P.J. Coenraads (rapporteur), G. Degen, M. Dusinska, W. Lilienblum, A. Luch, E. Nielsen, T. Platzek, S.C. Rastogi (chairman), C. Rousselle, J. van Benthem.

SCCS number: SCCS/1534/14.

Doi: 10.2772/47567.

Adopted on: Revision of 22 October 2014.

Link to the SCCS opinion: http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_160.pdf.

Acknowledgement

None.

Transparency document

Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2015.08.004.

^{*} Corresponding author.

E-mail address: SANTE-C2-SCCS@ec.europa.eu (Ms S.C. SCCS)

E-mail address: SANTE-C2-SCCS@ec.europa.eu (Scientific Committee SCCS).

¹ Rapporteur for the opinion.